Skip to main content
SpringerLink
Log in

What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?

  • Neuro-oncology (R Soffietti, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

The management of low-grade gliomas (grade II WHO) is still controversial, due to the rarity of these tumors and continuous advances in molecular diagnosis and new technologies for treatment. This article reviews the current understanding of management of grade II gliomas in light of the recent clinical and translational studies.

Recent findings

The role of an extensive surgery at onset is now fully recognized. Recent clinical trials in the USA and Europe have demonstrated the importance of chemotherapy either in association with radiotherapy or as initial treatment to delay the risk of cognitive defects following radiation. Molecular factors, such as IDH1 or 2 mutations and 1p/19q codeletion, are favorable prognostic factors, and seem to predict a better response to chemotherapy as well.

Summary

The role of conventional therapeutic options (surgery, radiotherapy, chemotherapy), in various combinations or sequences, has been better defined by clinical trials, but still there are areas of controversy. A future challenge is to reevaluate the role of these options within the different molecular subgroups of prognostic significance according to the last WHO classification of CNS tumors of 2016.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rudà R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro-Oncology. 2012;14(Suppl 4):iv55–64. https://doi.org/10.1093/neuonc/nos199.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100(12):2622–6. https://doi.org/10.1002/cncr.20297.

    Article  PubMed  Google Scholar 

  3. Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro-Oncology. 2013;15(5):595–606. https://doi.org/10.1093/neuonc/nos331.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gozé C, Blonski M, Le Maistre G, Bauchet L, Dezamis E, Page P, et al. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro-Oncology. 2014;16(8):1100–9. https://doi.org/10.1093/neuonc/nou085.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi-org.offcampus.dam.unito.it/10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  6. Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, et al. Cancer Genome Atlas Research Network comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98. https://doi.org/10.1056/NEJMoa1402121.

    Article  PubMed  CAS  Google Scholar 

  7. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508. https://doi.org/10.1056/NEJMoa1407279.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ragel BT, Ryken TC, Kalkanis SN, Ziu M, Cahill D, Olson JJ. The role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125(3):481–501. https://doi-org.offcampus.dam.unito.it/10.1007/s11060-015-1866-2

    Article  Google Scholar 

  9. Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, et al. Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg. 2008;51(5):275–9. https://doi.org/10.1055/s-0028-1082322.

    Article  PubMed  CAS  Google Scholar 

  10. • Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassification to novel treatment options. Semin Cancer Biol. 2017; https://doi.org/10.1016/j.semcancer.2017.11.010. An interesting translational review.

  11. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125(3):503–30. https://doi-org.offcampus.dam.unito.it/10.1007/s11060-015-1867-1

    Article  Google Scholar 

  12. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835–41. https://doi.org/10.3171/JNS/2008/109/11/0835.

    Article  PubMed  Google Scholar 

  13. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881–8. https://doi.org/10.1001/jama.2012.12807.

    Article  PubMed  CAS  Google Scholar 

  14. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103(6):1227–33. https://doi.org/10.1002/cncr.20867.

    Article  PubMed  Google Scholar 

  15. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700–7. https://doi.org/10.1227/01.NEU.0000325729.41085.73.

    Article  PubMed  Google Scholar 

  16. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–45. https://doi.org/10.1200/JCO.2007.13.9337.

    Article  PubMed  Google Scholar 

  17. Ahmadi R, Dictus C, Hartmann C, Zürn O, Edler L, Hartmann M, et al. Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir. 2009;151(11):1359–65. https://doi.org/10.1007/s00701-009-0435-x.

    Article  PubMed  Google Scholar 

  18. Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O'Neill BP, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-Oncology. 2009;11(4):437–45. https://doi.org/10.1215/15228517-2008-102.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg. 2010;112(1):10–7. https://doi.org/10.3171/2008.10.JNS08608.

    Article  PubMed  Google Scholar 

  20. Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. J Neurosurg. 2012;117(6):1039–52. https://doi.org/10.3171/2012.8.JNS12393.

    Article  PubMed  Google Scholar 

  21. Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, et al. French Réseau d'Étude des Gliomes. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013;118(6):1157–68. https://doi.org/10.3171/2013.1.JNS121.

    Article  PubMed  Google Scholar 

  22. Roelz R, Strohmaier D, Jabbarli R, Kraeutle R, Egger K, Coenen VA, et al. Residual tumor volume as best outcome predictor in low grade glioma—a nine-years near-randomized survey of surgery vs. biopsy. Sci Rep. 2016;6:32286. https://doi.org/10.1038/srep32286.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784–91.

    Article  PubMed  CAS  Google Scholar 

  24. Jiang B, Chaichana K, Veeravagu A, Chang SD, Black KL, Patil CG. Biopsy versus resection for the management of low-grade gliomas. Cochrane Database Syst Rev. 2017;4:CD009319. https://doi.org/10.1002/14651858.CD009319.pub3.

    Article  PubMed  Google Scholar 

  25. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17(9):1124–33. https://doi.org/10.1111/j.1468-1331.2010.03151.x.

    Article  PubMed  CAS  Google Scholar 

  26. Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection. Clinical article. J Neurosurg. 2011;115(2):232–9. https://doi.org/10.3171/2011.3.JNS101333.

    Article  PubMed  Google Scholar 

  27. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997–1003. https://doi.org/10.1016/S1470-2045(11)70196-6.

    Article  PubMed  Google Scholar 

  28. Duffau H, Peggy Gatignol ST, Mandonnet E, Capelle L, Taillandier L. Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with grade II glioma in the left dominant hemisphere. J Neurosurg. 2008;109(3):461–71. https://doi.org/10.3171/JNS/2008/109/9/0461.

    Article  PubMed  Google Scholar 

  29. Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011;114(3):566–73. https://doi.org/10.3171/2010.6.JNS091246.

    Article  PubMed  Google Scholar 

  30. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559–65. https://doi.org/10.1200/JCO.2011.38.4818.

    Article  PubMed  Google Scholar 

  31. Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012;70(4):921–8. https://doi.org/10.1227/NEU.0b013e31823c3a30.

    Article  PubMed  Google Scholar 

  32. • DS X, Awad AW, Mehalechko C, Wilson JR, Ashby LS, Coons SW, et al. An extent of resection threshold for seizure freedom in patients with low-grade gliomas. J Neurosurg. 2018;128(4):1084–90. https://doi.org/10.3171/2016.12.JNS161682. Clinical paper suggesting the existence of a threshold of extent of resection for seizure freedom.

    Article  Google Scholar 

  33. •• Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55. https://doi.org/10.1200/JCO.2003.06.02310.1056/NEJMoa1500925. Phase III US trial demonstrating that the addition of PCV chemotherapy to radiotherapy is superior in terms of PFS and OS to radiotherapy alone in high-risk grade II gliomas.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. •• Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521–32. https://doi.org/10.1016/S1470-2045(16)30313-8. Phase III US trial demonstrating that the addition of PCV chemotherapy to radiotherapy is superior in terms of PFS and OS to radiotherapy alone in high-risk grade II gliomas.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985–90. https://doi.org/10.1016/S0140-6736(05)67070-5.

    Article  PubMed  Google Scholar 

  36. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361–8.

    Article  PubMed  CAS  Google Scholar 

  37. Laack NN, Brown PD, Ivnik RJ, Furth AF, Ballman KV, Hammack JE, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005;63(4):1175–83. https://doi.org/10.1016/j.ijrobp.2005.04.016.

    Article  PubMed  Google Scholar 

  38. Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–8. https://doi.org/10.1016/S1474-4422(09)70204-2.

    Article  PubMed  Google Scholar 

  39. Soffietti R, Rudà R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43(5):1066–73.

    Article  PubMed  CAS  Google Scholar 

  40. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715–21.

    Article  PubMed  CAS  Google Scholar 

  41. Buckner JC, Gesme D Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21(2):251–5. https://doi.org/10.1200/JCO.2003.06.023.

    Article  PubMed  CAS  Google Scholar 

  42. Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.

    Article  PubMed  CAS  Google Scholar 

  43. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133–8. https://doi.org/10.1200/JCO.2004.10.169.

    Article  PubMed  CAS  Google Scholar 

  44. • Wu J, Neale N, Huang Y, Bai HX, Li X, Zhang Z, et al. Comparison of adjuvant radiation therapy alone and chemotherapy alone in surgically resected low-grade gliomas: survival analyses of 2253 cases from the National Cancer Data Base. World Neurosurg. 2018;112:e812–22. https://doi.org/10.1016/j.wneu.2018.01.163. An interesting real-life analysis of patterns of adjuvant treatment in low-grade gliomas.

    Article  PubMed  Google Scholar 

  45. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012 Sep 1;30(25):3065–70. https://doi.org/10.1200/JCO.2011.35.8598.

  46. Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma. J Neuro-Oncol. 2017 Dec;135(3):535–43. https://doi.org/10.1007/s11060-017-2599-1.

  47. Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys. 2015;91(3):497–504. https://doi.org/10.1016/j.ijrobp.2014.11.012.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. • Jhaveri J, Liu Y, Chowdhary M, Buchwald ZS, Gillespie TW, Olson JJ, et al. Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: an analysis of the National Cancer Data Base. Cancer. 2018;124(6):1169–78. https://doi.org/10.1002/cncr.31158. A large retrospective analysis on National US Cancer Database comparing chemotherapy alone with chemotherapy and radiation for high-risk grade II gliomas.

    Article  PubMed  CAS  Google Scholar 

  49. • Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-Oncology. 2017;19(2):242–51. https://doi.org/10.1093/neuonc/now176. Large monoinstitutional prospective study investigating chemotherapy with temozolomide as initial treatment to delay radiation therapy

    Article  PubMed  Google Scholar 

  50. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–93. https://doi.org/10.1126/science.1239947.

    Article  PubMed  CAS  Google Scholar 

  51. Rudà R, Soffietti R. Extent of surgery in low-grade gliomas: an old question in a new context. Neuro-Oncology. 2018;20(1):6–7. https://doi.org/10.1093/neuonc/nox218.

    Article  PubMed  Google Scholar 

  52. • Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–8. https://doi.org/10.1093/annonc/mdx230. An interesting retrospective study suggesting that resection is to be preferred to a biopsy regardless of molecular subtype.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. • Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology. 2018;20(1):103–12. https://doi.org/10.1093/neuonc/nox176. Interesting paper suggesting that IDH-mutated but not 1p/19q codeleted gliomas derive the maximal benefit from gross total resection.

    Article  PubMed  Google Scholar 

  54. • Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, et al. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol. 2018;135(4):601–15. https://doi.org/10.1007/s00401-018-1810-6. An interesting translational review suggesting that an MGMT methylation score may predict benefit from chemotherapy alone in a large cohort of low-grade gliomas.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. • Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, et al. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology. 2017;19(10):1327–37. https://doi.org/10.1093/neuonc/nox078. A large retrospective study reporting a molecular heterogeneity of IDH 1-2 wild-type lower grade gliomas.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol. 2017;134(6):957–9. https://doi.org/10.1007/s00401-017-1781-z.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The editors would like to thank Dr. Myrna Rosenfeld for taking the time to review this manuscript.

Author information

Authors and Affiliations

  1. Department of Neuro-Oncology, University and City of Health and Science, Via Cherasco 15, 10126, Turin, Italy

    Roberta Rudà MD, Francesco Bruno MD & Riccardo Soffietti MD

Authors
  1. Roberta Rudà MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Bruno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riccardo Soffietti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberta Rudà MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by of the authors.

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rudà, R., Bruno, F. & Soffietti, R. What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?. Curr Treat Options Neurol 20, 33 (2018). https://doi.org/10.1007/s11940-018-0516-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-018-0516-3

Keywords

Search

Navigation